连续降钙素原监测预测严重脓毒症患者死亡率:多中心降钙素原监测脓毒症(MOSES)研究结果
MOSES研究为美国13个急诊科与ICU开展的前瞻性、盲法、多中心观察性临床试验,纳入858例严重脓毒症或脓毒性休克患者,前5天每日监测降钙素原。主要分析纳入第4天仍存活且住院的646例患者,比较基线至第4天降钙素原降幅是否超过80%与28天全因死亡率的关系。降幅未超过80%者28天全因死亡率为20%,降幅超过80%者为10%(p=0.001);校正人口学、APACHE II评分、第4天ICU停留、脓毒症综合征严重度、抗生素给药时间等混杂因素后,降幅未超过80%仍是独立预测因子(HR 1.97,95%CI 1.18-3.30,p<0.009)。作者认为该指标可能有助于脓毒症诊疗。
要点
- 严重脓毒症或脓毒性休克患者基线至第4天降钙素原降幅未超过80%时,28天全因死亡率为20%,降幅超过80%者为10%(p=0.001)。
- 校正人口学、APACHE II、第4天ICU停留、脓毒症严重度、抗生素给药时间等混杂因素后,降幅未超过80%仍是死亡的独立预测因子(HR 1.97,95%CI 1.18-3.30,p<0.009)。
- 主要分析纳入858例中第4天仍存活且住院的646例患者,降钙素原在前5天每日测量。
- 研究为美国13个急诊科与ICU的前瞻性、盲法、多中心观察性临床试验,遵循FDA批准的方案。
适用人群与场景
- 纳入标准:符合严重脓毒症或脓毒性休克标准、从急诊科、其他病房或院外直接收入ICU的连续患者。
- 主要分析人群:858例入组患者中第4天仍存活且住院的646例患者。
诊断标准与关键阈值
- 主要暴露指标:基线至第4天降钙素原降幅是否超过80%。
处置流程与药物剂量
- 前5天每日测量降钙素原。
研究设计与关键结果
- 研究类型:前瞻性、盲法、多中心观察性临床试验,遵循FDA批准的方案。
- 样本量与中心数:858例入组,来自美国13个急诊科与ICU;主要分析纳入646例第4天仍存活且住院的患者。
- 主要终点:降钙素原降幅未超过80%者28天全因死亡率为20%,降幅超过80%者为10%(p=0.001)。
- 校正人口学、APACHE II评分、第4天ICU停留、脓毒症综合征严重度、抗生素给药时间及其他相关混杂因素后,降幅未超过80%是死亡的独立预测因子(HR 1.97,95%CI 1.18-3.30,p<0.009)。
证据类型、等级与局限
- 证据类型:前瞻性多中心观察性临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基线至第4天降钙素原降幅未超过80%是死亡的显著独立预测因子,可能有助于脓毒症诊疗。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To prospectively validate that the inability to decrease procalcitonin levels by more than 80% between baseline and day 4 is associated with increased 28-day all-cause mortality in a large sepsis patient population recruited across the United States.
DESIGN: Blinded, prospective multicenter observational clinical trial following an Food and Drug Administration-approved protocol.
SETTING: Thirteen U.S.-based emergency departments and ICUs.
PATIENTS: Consecutive patients meeting criteria for severe sepsis or septic shock who were admitted to the ICU from the emergency department, other wards, or directly from out of hospital were included.
INTERVENTIONS: Procalcitonin was measured daily over the first 5 days.
MEASUREMENTS AND MAIN RESULTS: The primary analysis of interest was the relationship between a procalcitonin decrease of more than 80% from baseline to day 4 and 28-day mortality using Cox proportional hazards regression. Among 858 enrolled patients, 646 patients were alive and in the hospital on day 4 and included in the main intention-to-diagnose analysis. The 28-day all-cause mortality was two-fold higher when procalcitonin did not show a decrease of more than 80% from baseline to day 4 (20% vs 10%; p = 0.001). This was confirmed as an independent predictor in Cox regression analysis (hazard ratio, 1.97 [95% CI, 1.18-3.30; p < 0.009]) after adjusting for demographics, Acute Physiology and Chronic Health Evaluation II, ICU residence on day 4, sepsis syndrome severity, antibiotic administration time, and other relevant confounders.
CONCLUSIONS: Results of this large, prospective multicenter U.S. study indicate that inability to decrease procalcitonin by more than 80% is a significant independent predictor of mortality and may aid in sepsis care.
参考来源
- Schuetz P, Birkhahn R, Sherwin R, et al. Serial Procalcitonin Predicts Mortality in Severe Sepsis Patients: Results From the Multicenter Procalcitonin MOnitoring SEpsis (MOSES) Study. Crit Care Med. 2017. PMID: 28257335. doi:10.1097/CCM.0000000000002321
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。